Every open market buy and sale of Ocular Therapeutix, Inc stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are net sellers over the last 12 months: $461K bought and $3.3M sold.
Buying and selling by month
open market, last 12 monthsGet an alert when OCUL insiders trade
We read every Form 4 the moment the SEC posts it and tell you when an OCUL officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.
Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.
Every OCUL insider trade
2 years · newest first| Insider | Type | Price | Held after | Filed | |||
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | Namrata SarojChief Business Officer | Sale plan | 35,370 | $6.55 | $232K | 220,522 | Nov 9Form 4 |
| Oct 8, 2026 | Todd AndermanChief Legal Officer | Sale plan | 11,984 | $7.29 | $87K | 140,484 | Oct 13Form 4 |
| Oct 2, 2026 | Jeffrey S. HeierChief Scientific Officer | Sale plan | 10,869 | $7.05 | $77K | 307,457 | Oct 6Form 4 |
| Oct 2, 2026 | Peter KaiserChief Development Officer | Sale plan | 9,990 | $7.05 | $70K | 254,388 | Oct 6Form 4 |
| Aug 31, 2026 | Donald NotmanCOO | Sale | 1,099 | $10.24 | $11K | 366,529 | Sep 2Form 4 |
| Aug 24, 2026 | Pravin DugelSee Remarks | Sale plan | 21,649 | $10.77 | $233K | 2,525,429 | Aug 26Form 4 |
| Aug 24, 2026 | Jeffrey S. HeierChief Scientific Officer | Sale plan | 3,296 | $10.78 | $36K | 318,326 | Aug 26Form 4 |
| Aug 24, 2026 | Sanjay NayakChief Strategy Officer | Sale plan | 1,897 | $10.78 | $20K | 326,898 | Aug 26Form 4 |
| Aug 24, 2026 | Peter KaiserChief Development Officer | Sale plan | 3,035 | $10.77 | $33K | 264,378 | Aug 26Form 4 |
| Jun 3, 2026 | Nadia WaheedChief Medical Officer | Sale plan | 14,828 | $8.27 | $123K | 300,079 | Jun 5Form 4 |
| May 26, 2026 | Sanjay NayakChief Strategy Officer | Sale plan | 1,858 | $8.20 | $15K | 328,795 | May 28Form 4 |
| May 26, 2026 | Jeffrey S. HeierChief Scientific Officer | Sale plan | 3,018 | $8.20 | $25K | 320,350 | May 28Form 4 |
| May 26, 2026 | Peter KaiserChief Development Officer | Sale plan | 2,967 | $8.20 | $24K | 266,141 | May 28Form 4 |
| May 26, 2026 | Pravin DugelSee Remarks | Sale plan | 21,156 | $8.20 | $173K | 2,597,170 | May 28Form 4 |
| Feb 23, 2026 | Sanjay NayakChief Strategy Officer | Sale plan | 1,759 | $8.28 | $15K | 330,653 | Feb 25Form 4 |
OCUL insider trading FAQ
Are OCUL insiders buying or selling?
Insiders are net sellers over the last 12 months. 1 insiders bought $461K of OCUL on the open market in 1 trades, and 8 sold $3.3M in 28 trades, 93% of that under pre-arranged trading plans.
When did an OCUL insider last buy shares?
Richard L Lindstrom Md (Director) bought 60,229 shares for $461K on Feb 20, 2026, reported on Feb 24, 2026.
When did an OCUL insider last sell shares?
Namrata Saroj (Chief Business Officer) sold 35,370 shares for $232K on Nov 5, 2026, under a pre-arranged trading plan.
What is a Form 4?
Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.
Why do insider sales matter less than buys?
Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.
From SEC Form 4 filings · Not investment advice
